Q-linea Ab · OMXSTO:QLINEA
Q-linea Ab — Q1 2023 Earnings Presentation
18 slides from Q-linea Ab's earnings presentation, May 4, 2023
Slide 1: Future Proof Healthcare
FUTURE PROOF HEALTHCARE A sustainable healthcare for a new generation Presentation Q1(23) Jonas Jarvius, CEO Christer Samuelsson, CFO/IR
Slide 2: Disclaimer
Disclaimer DISCLAIMER THIS PR ES ENTATION AND I TS CONTENTS ARE CONFID EN TIAL AND ARE NOT FOR R EL EAS E, PUBLICA TION OR DISTRIB UTION, IN WHOL E OR IN PART, DIREC TL Y OR INDIRECTLY, IN OR INTO OR FROM THE UNI TED S TA TES OF AM ERICA, CANA DA, AUSTR ALIA, JAP AN OR ANY OTHER J URIS DICTION WHERE
Slide 3: Q-linea 1st quarter
Headquarters, Marketing and demo lab, Consumable production in Uppsala Q-linea 1st quarter Q-linea is developing disruptive solutions for faster infectious disease diagnostics, first product targeting sepsis Introduction to the company Lead product ASTar® Implementation of new commercialisation stra
Slide 4: Time to actionable results is important
Time to actionable results is important Sepsis is the most common cause of death in our hospitals More common than lung + prostate + breast-cancer combined Accounts for approximate 30% of all deaths in the hospital Most expensive condition to treat in the US. >27B USD 1) Time to correct treatment is
Slide 5: Rapid AST & a broad antimicrobial panel matters
Rapid AST & a broad antimicrobial panel matters: ASTar can provide up to 48 hours faster actionable results Transportation of blood culture from patient to laboratory: 1 – 24+ hours DAY 1 DAY 2 DAY 3 DAY 4 Plates are streaked CURRENT WORKFLOW Gram Susceptibility Patient to perform a Colony blood dra
Slide 6: ASTar performance is strong and it is easy to use
ASTar performance is strong and it is easy to use Evaluation of commercial systems for rapid antimicrobial susceptibility testing (rAST) of positive blood cultures: Comparison of susceptibility results View Sheffield Hospital’s scientific poster presentation from ECCMID 2022, featuring the ASTar Sys
Slide 7: ASTar makes a difference in patient outcome
ASTar makes a difference in patient outcome Patient-case from commercial evaluation in Sweden ASTar results Patient • ASTar results at least 18 h earlier than Std-AST. • Man, 64, surgery department • MIC results from 13 additional antibiotics • Empiric treatment Piperacillin/tazobactam • Resistant a
Slide 8: Q-linea 1st quarter
Headquarters, Marketing and demo lab, Consumable production in Uppsala Q-linea 1st quarter A summary of events coming into the 1st quarter 2023 October 2022 26th Thermo Fisher Scientific & Q-linea jointly terminate distribution agreement Introduction to the company Q-linea immediately starts to deve
Slide 9: Q-linea 1st quarter
Headquarters, Marketing and demo lab, Consumable production in Uppsala Q-linea 1st quarter A summary of events coming into the 1st quarter 2023 and after period end, contd. March 2023 16th A hospital in Belgium receives ethical approval for ASTar clinical impact study Introduction to the company Apr
Slide 10: Trading of shares and Q-linea share price
Trading of shares and Q-linea share price >1,500,000 shares sold by two large owners – put an immense pressure on the share Share price development and large changes in ownership of shares 3 000 000 80 70 2 500 000 Q-linea share price Number of shares 60 2 000 000 50 1 500 000 40 30 1 000 000 20 500
Slide 11: Tentative market for rAST from blood cultures in 2025
Tentative market for rAST from blood cultures in 2025 If one assumes that rAST is important for patients with Sepsis Sepsis Positive blood cultures 1) Assume 20% eligible for If equally divided by selected 20 M testing with rAST 1) current rAST providers 4 M test 1 M test Key: Primary markets Other
Slide 12: Updated commercialisation strategy – first stage in 2023
Updated commercialisation strategy – first stage in 2023 Initially focus on key geographies in Europe and East coast in the USA & at the same time manage costs Goal is to demonstrate ASTar commercially USA – Q-linea Inc. & Most important market due to Enable a strong ramp-up in size and demonstrated
Slide 13: Poland will be the first country in Europe…
Poland will be the first country in Europe… To commit resources for large scale focus on improved diagnostics for septic patients 2023 will be an important year in Poland with a clear focus on improved diagnostic capabilities for patients with sepsis Particular focus will be on rAST technology Q-lin
Slide 14: Current commercialization status, progress in all areas
Current commercialization status, progress in all areas One important lesson from 2022 is that the sales process is long, 9-15 months. One reason is that rAST is a new field within microbiology and changes take time Customer want to evaluate ASTar in their lab and compare to other rAST systems We se
Slide 15: Consolidated statement of profit and loss - first quarter
Consolidated statement of profit and loss - first quarter Net sales in the first quarter amounted to SEK 0 million (5.8). Operating result totalled SEK -62.2 million (-71.5). The company reported a loss after tax of SEK -61.4 million (-72.8). Earnings per share, before and after dilution amounted to
Slide 16: Consolidated statement of financial position - end of first quarter
Consolidated statement of financial position - end of first quarter Cash and cash equivalents amounted to SEK 20.6 million (72.9). Inventories amounted to SEK 48.2 million (42.3). Equity amounted to SEK 102.6 million (163.2) Loan from principal owner SEK 24.8 million (0) Figures in parentheses refer
Slide 17: Cash flow statement first quarter
Cash flow statement first quarter Cash flow from operating activities SEK -72.4 million (-50.0). Increase in cash outflow from operating activities mainly due to unfavourable changes in the working capital compared to the same quarter last year which is partly offset by higher Operating result. Cash
Slide 18: Thank you
Looking forward to an exciting continuation of 2023 Q-linea wants to contribute to a healthier society by future- proofing a new generation of healthcare professionals, labs and hospitals. Thank you 18